BioAge Labs (BIOA) Revenue Quarterly: History & Chart

BioAge Labs Inc.(BIOA)

Biotechnology · Emeryville, CA

$6.23-0.13 (-2.05%)

Delayed quote: Oct 6, 2026, 10:30 AM EDT

About BioAge Labs Inc.

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Emeryville, CA

61 employees

bioagelabs.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Kristen Fortney

View full financials

Quarterly Revenue

Basis: latest reported fiscal quarter (Q2 FY2026). Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly revenue is $2.45M with QoQ Growth of (11.58%). Quarterly revenue is the total sales generated during the latest fiscal quarter.

Revenue TTM|Revenue Annual|Revenue CAGR|Financials

Quarterly Revenue

BIOA Quarterly Revenue

$2.45M

Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $2.45M.

BIOA P/S Ratio

Full P/S Ratio page

P/S Ratio

BIOA P/S Ratio Chart

22.65

FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:30:52.412Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

BIOA EV/Sales

Full EV/Sales page

EV/Sales

BIOA EV/Sales Chart

15.78x

Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:30:52.412Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

Quarterly Revenue History

Period	Quarterly Revenue	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$2.45M	(11.58%)	N/A
Q1 FY2026Period end 2026-03-31	$2.77M	(9.94%)	N/A
Q4 FY2025Period end 2025-12-31	$3.08M	+49.85%	N/A
Q3 FY2025Period end 2025-09-30	$2.05M	N/A	N/A
Q2 FY2025Period end 2025-06-30	$2.41M	+66.23%	N/A
Q1 FY2025Period end 2025-03-31	$1.45M	N/A	N/A
Q4 FY2024Period end 2024-12-31	$0	N/A	N/A
Q3 FY2024Period end 2024-09-30	$0	N/A	N/A
Q2 FY2024Period end 2024-06-30	$0	N/A	N/A
Q1 FY2024Period end 2024-03-31	$0	N/A	N/A
Q4 FY2023Period end 2023-12-31	$0	N/A	N/A
Q3 FY2023Period end 2023-09-30	$0	N/A	N/A
Q2 FY2023Period end 2023-06-30	$0	N/A	N/A
Q1 FY2023Period end 2023-03-31	$0	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.